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Abstract
Background: Inflammatory responses in the CNS mediated by activated glial cells play an important role in host-
defense but are also involved in the development of neurodegenerative diseases. Resveratrol is a natural
polyphenolic compound that has cardioprotective, anticancer and anti-inflammatory properties. We investigated
the capacity of resveratrol to protect microglia and astrocyte from inflammatory insults and explored mechanisms
underlying different inhibitory effects of resveratrol on microglia and astrocytes.
Methods: A murine microglia cell line (N9), primary microglia, or astrocytes were stimulated by LPS with or
without different concentrations of resveratrol. The expression and release of proinflammatory cytokines (TNF-a, IL-
1b, IL-6, MCP-1) and iNOS/NO by the cells were measured by PCR/real-time PCR and ELISA, respectively. The
phosphorylation of the MAP kinase superfamily was analyzed by western blotting, and activation of NF-B and AP-
1 was measured by luciferase reporter assay and/or electrophoretic mobility shift assay.
Results: We found that LPS stimulated the expression of TNF-a, IL-1b, IL-6, MCP-1 and iNOS in murine microglia
and astrocytes in which MAP kinases, NF-B and AP-1 were differentially involved. Resveratrol inhibited LPS-
induced expression and release of TNF-a, IL-6, MCP-1, and iNOS/NO in both cell types with more potency in
microglia, and inhibited LPS-induced expression of IL-1b in microglia but not astrocytes. Resveratrol had no effect
on LPS-stimulated phosphorylation of ERK1/2 and p38 in microglia and astrocytes, but slightly inhibited LPS-
stimulated phosphorylation of JNK in astrocytes. Resveratrol inhibited LPS-induced NF-B activation in both cell
types, but inhibited AP-1 activation only in microglia.
Conclusion: These results suggest that murine microglia and astrocytes produce proinflammatory cytokines and
NO in response to LPS in a similar pattern with some differences in signaling molecules involved, and further
suggest that resveratrol exerts anti-inflammatory effects in microglia and astrocytes by inhibiting different
proinflammatory cytokines and key signaling molecules.
Background
Microglia, the resident macrophage-like cells in the
brain, play an important role in host defense and tissue
repair in CNS [1,2]. Activated microglia produce a vari-
ety of pro-inflammatory mediators, including tumor
necrosis factor a (TNF-a), interleukin-1b (IL-1b), IL-6,
monocyte chemotactic protein 1 (MCP-1, CCL2), nitric
oxide (NO), and reactive oxygen species (ROS).
Activated microglia serve immune surveillance functions
by removing foreign microorganisms, but may also
result in excessive inflammatory responses in the CNS
[1,2]. Astrocytes are the main glial cell type in the brain
involved in maintaining CNS homeostasis. They also
respond promptly to injury and regulate neuroinflam-
matory events [2-4]. Both in vitro and in vivo studies
have documented the ability of astrocytes to produce a
variety of cytokines, including IL-1, IL-6, IL-10, inter-
feron-a (INF-a), IFN-b,T N F - a,T N F - b; and chemo-
kines, including RANTES (CCL5), IL-8 (CXCL8) and
MCP-1 [3]. Over-activation of glial cells and release of
proinflammatory cytokines may lead to neuronal death
[5-7], causing neuropathological changes in CNS
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any medium, provided the original work is properly cited.diseases such as multiple sclerosis [8,9], Parkinson’sd i s -
ease [10,11], Alzheimer’s disease [12] and AIDS demen-
tia [13]. Therefore, limiting inflammatory cytokine
production by activated microglia and astrocytes should
be beneficial for prevention of neuroinflammation and
neurodegeneration.
Resveratrol (3,4’,5-trihydroxy-trans-stilbene) is a poly-
phenolic compound found in a large number of plant
species that are components of human diet, including
mulberries, peanuts, grapes and red wine. Accumulating
evidence suggests that resveratrol may exert a protective
effect in the CNS under pathological conditions, and
that resveratrol is associated with reduced risks of cardi-
ovascular disease, cancer, diabetes and AD [14-17].
Resveratrol has also been proposed to be an anti-inflam-
matory molecule [18]. In glial cells, resveratrol has been
reported to inhibit LPS-induced production of NO and
TNF-a by the murine microglia cell line N9 [19,20]; to
inhibit prostaglandin E2 (PGE2) and free radical produc-
tion by rat primary microglia [21], and to inhibit NO
and PGE2 by the rat astroglial cell line C6 [22]. Micro-
glia and astrocytes are two cell types with different bio-
logical characteristics and functions in the CNS, it is not
clear if there are differences between these cells in
response to LPS or if resveratrol inhibits the inflamma-
tory responses of these cells to LPS through similar
mechanisms.
In the present study, we first examined the expression
of various proinflammatory cytokines (TNF-a,I L - 1 b,
IL-6, MCP-1) and of iNOS by murine microglia and
astrocytes in response to LPS, and the signaling mole-
cules involved. We then determined the effects of
resveratrol on microglial cell and astrocyte activation by
LPS, and explored the underlying key signaling
molecules.
Methods
Materials
Resveratrol, LPS and MTT were obtained from Sigma
(St. Louis, MO). PD98059, SP600125, SB203580, sulfa-
salazine and curcumin were from Calbiochem (Darm-
stadt, Germany). Antibodies against both
phosphorylated and unphosphorylated extracellular sig-
nal-regulated kinases (ERK1/2), p38, c-jun N-terminal
kinase (JNK) were obtained from Cell Signaling Tech-
nology (New England Biolabs, Beverly, MA). Dual-
Luciferase Reporter Assay System was from Promega
Corporation (Woods Hollow Road, Madison, USA).
LightShift Chemiluminescent EMSA kit was from
Pierce (Pierce, Rockford, IL, USA). DMEM was pur-
chased from Gibco BRL (Burlington, Ontario, Canada).
Fetal bovine serum (FBS) was from Hyclone (Logan,
UT). All other reagents were obtained from Sigma-
Aldrich unless otherwise described.
Glial cell cultures
Primary mouse microglia were isolated and purified from
whole brain of newborn C57BL/6 mice as previously
described [23]. Briefly, brain tissues were minced into
small pieces. Cells were separated by trypsinization and
cultured in 75 cm
2 tissue culture flasks with DMEM med-
ium containing 10% FBS, 100 μmol/L non-essential amino
acids, 5 μg/mL insulin, 100 U/mL penicillin and 100 μg/
mL streptomycin. When cells grew to confluence (7-10 d),
flasks were shaken overnight (200 rpm at 37°C) to loosen
microglia and oligodendrocytes from the more adherent
astrocytes. These less adherent cells were plated for 1 h
and then lightly shaken to separate oligodendrocytes from
the more adherent microglia. Microglia were seeded in
cell culture plates for future use. After shaking to remove
microglia and oligodendrocytes, the adherent astrocytes
were purified by trypsinization, seeded in cell culture
plates for 30 min, and removed adherent microglia. The
purity of primary microglia and astrocytes is greater than
97% as determined by immunocytochemistry with antibo-
dies against CD11b and glial fibrillary acidic protein
(GFAP), respectively (Fig. 1). All experiments using mice
were in accordance with the National Institutes of Heath
G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l sa n d
were approved by the Biological Research Ethics Commit-
tee, Institute for Nutritional Sciences, Chinese Academy of
Sciences. The murine microglial cell line N9 was a kind
gift from P. Ricciardi-Castagnoli (Universita Degli Studi di
Milano-Bicocca, Milan, Italy) [24]. The cells were grown
in IMDM supplemented with 5% heat-inactivated FBS, 2
mmol/L glutamine, 100 U/mL penicillin, 100 μg/mL strep-
tomycin, and 10 μmol/L 2-ME.
Immunofluorescence staining
Murine primary microglia or astrocytes were cultured
on slides in 24-well plates. The cells were fixed with 4%
paraformaldehyde for 10 min at room temperature,
washed with PBS, and then incubated with 5% BSA/
PBS, 0.01% Tween-20 at room temperature for an addi-
tional 1 h. Rat anti-CD11b (1:25, BD Bioscience) or
anti-GFAP (1:100, Zymed) antibody was applied to the
slides and incubated overnight at 4°C. Rat IgG (Santa
Cruz) was used as negative control. The slides were
washed and incubated with FITC-conjugated goat anti-
rat IgG (1:200) for 60 min, washed with PBS, stained
with Hoechst 33342, and mounted. Immunofluorescence
labeling was observed under a fluorescent microscope.
RT-PCR and real-time PCR
Cells were cultured in medium without FBS for 24 h,
then treated with 0.5 μg/mL LPS with or without
various concentrations of resveratrol for another 8 h.
Total RNA was extracted from cells with Trizol reagent
(Invitrogen) and depleted of contaminating DNA with
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RNA with M-MuLV reverse transcriptase and random
hexamer according to manufacturer’si n s t r u c t i o n s( F e r -
m e n t a s ,B u r l i n g t o n ,O n t a r i o ,C a n a d a ) .At o t a lo f2μL
reverse transcription products was used for PCR. PCR
products were visualized by ethedium bromide staining
in 1.5% agarose gel and quantified using Gel-Pro Analy-
zer software (Media Cybernetics Inc., Silver Spring,
Maryland, USA). Amplification of the target cDNA was
normalized to b-actin expression. All experiments were
replicated at least three times.
Quantitative real-time PCR was performed by using an
ABI Prism 7500 sequence detector (Applied Biosystems
Inc, Foster City, CA). Briefly, reverse-transcribed cDNA
in duplicate samples were checked for cytokine or che-
mokine mRNA levels with SYBR Green PCR master kit
(TOYOBO Biotech, Osaka, Japan) according to manu-
facture’s instruction. The assays were initiated with
5 min at 95°C, and then 40 cycles of 15 s at 94°C, 1 min
at 60°C. Amplification of the target cDNA was normal-
ized to b-actin expression. Relative levels of target
mRNA expression were calculated using the 2
-ΔΔCT
method. The primers for PCR and real-time PCR were
listed in Table 1 and Table 2, respectively.
MTT assay
Cells cultured in 96-well cell culture plates were treated
with various concentrations of resveratrol with or
Figure 1 Immunofluorescence staining of murine primary microglia and astrocytes with anti-CD11B and anti-GFAP antibodies,
respectively. Data are representative of three independent experiments with similar results.
Table 1 PCR primers
Gene PCR primers
TNFa sense: 5’-ATGAGCACAGAAAGCATGATCCGCG
antisense: 5’-CCCTTCACAGAGCAATGACTCCAAA
IL-1b sense: 5’-ATGGCAACTGTTCCTGAACTCAACT
antisense: 5’-AGGACAGGTATAGATTCTTTCCTTT
IL-6 sense: 5’-GATGCTACCAAACTGGATATAATC
antisense: 5’-GGTCCTTAGCCACTCCTTCTGTG
MCP-1 sense: 5’-CTCACCTGCTGCTACTCATTC
antisense: 5’-GCTTGAGGTGGTTGTGGAAAA
iNOS sense: 5’-TGGGAATGGAGACTGTCCCAG
antisense: 5’-GGGATCTGAATGTGATGTTTG
b-actin sense: 5’-TGTGATGGTGGGAATGGGTCAG
antisense: 5’-TTTGATGTCACGCACGATTTCC
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medium was removed and the cells were incubated with
MTT (0.25 mg/ml) for 5 h at 37°C. The formazan crys-
tals in the cells were solubilized with DMSO. The absor-
bance at 550 nm was determined by a microplate reader
Multiskan JX (Themo LabSystems). Cell viability was
expressed as a percentage of control.
LDH assay
Cells were treated with different concentrations of
resveratrol with or without 0.5 μg/ml LPS for 8 h. The
supernatant was collected and LDH release was detected
using a cytotox 96® nonradioactive cytotoxicity assay kit
(Promega) according to manufacture’si n s t r u c t i o n s .C e l l
viability was expressed as a percentage of control.
NO assay
Production of NO was determined by measuring the
accumulated level of nitrite (an indicator of NO) in the
supernatant after 24 h of LPS treatment with or without
different concentrations of resveratrol using a colori-
metric reaction with Griess reagent [25]. Briefly, 100 μL
of supernatant were mixed with 100 μL Griess reagent
[0.1% N-(1-naphthyl) ethylenediamine dihydrochloride,
1% sulfanilamide, and 2.5% H3PO4]. After incubation at
room temperature in the dark for 10 min, total nitrites
were measured spectrophotometrically at 540 nm. The
concentration of nitrite in the sample was determined
from a NaNO2 standard curve.
Proinflammatory cytokine measurement by ELISA
Microglial cells (2 × 10
4/well) or astrocytes (1 × 10
4/well)
were seeded into 48-well plates and cultured for 24 h.
Cells were then washed twice with DPBS, and incubated
in serum-free DMEM with or without different concen-
trations of resveratrol for 30 min followed by 0.5 μg/mL
LPS for an additional 24 h. The supernatants were col-
lected for measurement of TNFa,I L - 6 ,a n dM C P - 1 ;a n d
cell lysate were made for detecting IL-1b; using ELISA as
described by the manufacturer (Biosourse International).
Western immunoblotting
N9 cells or murine primary astrocytes were grown in
60-mm dishes until subconfluency and then were cul-
tured overnight in medium in the absence of FBS. The
cells were pretreated with different concentrations of
resveratrol for 1 h followed by LPS for different times
(N9 cells: 30 min, astrocytes: 20 min), then were lysed
with cold lysis buffer as described previously [26]. Cell
lysate proteins were electrophoresed on a 10% SDS-
PAGE gel, and transferred onto polyvinylidene difluoride
membranes (Millipore Corporation, Bedford, MA). The
membranes were blocked with 5% nonfat milk, and then
were incubated with anti-phosphorylated ERK1/2, p38
or JNK antibody overnight at 4°C. After incubation with
an HRP-conjugated secondary antibody, the protein
bands were detected with a Supersignal West Pico che-
miluminescenct substrate (Pierce, Rockford, IL) and X-
Omat BT film (Eastman Kodak Company, Rochester,
New York). For detection of total ERK1/2, p38, or JNK,
the membranes were stripped with Restore Western
Blot Stripping Buffer (Pierce, R o c k f o r d ,I L ) ,f o l l o w e db y
incubation with specific antibodies. Immunoblot results
were quantified using Gel-Pro Analyzer software (Media
Cybernetics Inc., Silver Spring, Maryland, USA).
Transient transfection and NF-B luciferase reporter assay
One day before transfection, murine primary microglial
cells (1 × 10
5/well) or astrocytes (0.5 × 10
5/well) were
seeded into 24-well plates. Transient transfection of pNF-
B-Luc plasmid and control vector (a generous gift from
Dr. J. Lu, Second Military Medical University, China) was
performed using Lipofectamin 2000 according to the man-
ufacture’s recommendations. A pRL-TK-Renilla vector
was used as an internal control for normalization of trans-
fection and harvesting efficiency. The cells were cultured
with transfection mixture for 5 h, and were then cultured
in DMEM containing 10% FBS, 0.5 μg/mL LPS with or
without different concentrations of resveratrol for 16 h.
Luciferase activity of pNF-B-Luc and pRL-TK constructs
was measured sequentially using the Dual-Luciferase
Reporter Assay System (Promega). Variation in transfec-
tion efficiency was normalized by dividing the promoter
construct activity by the respective co-transfected pRL-TK
luciferase activity. Promoter activity of the NF-Bw a s
expressed in units relative to values measured in cells
cultured with control medium.
Nuclear extract preparation and electrophoretic mobility
shift assay (EMSA)
Nuclear extracts were prepared as previously described
[27]. Protein concentration was determined using a
Table 2 Real-time PCR primers
Gene Real-time PCR primers
TNF-a sense: 5’-AGCCGATGGGTTGTACCTTGTCTA
antisense: 5’- TGAGATAGCAAATCGGCTGACGGT
IL-1b sense: 5’-ACAGAATATCAACCAACAAGTGATATTCTC
antisense: 5’-GATTCTTTCCTTTGAGGCCCA
IL-6 sense: 5’-ATCCAGTTGCCTTCTTGGGACTGA
antisense: 5’-TAAGCCTCCGACTTGTGAAGTGGT
MCP-1 sense: 5’-CCCACTCACCTGCTGCTACT
antisense: 5’-TCTGGACCCATTCCTTCTTG
iNOS sense: 5’-GGCAGCCTGTGAGACCTTTG
antisense: 5’-GAAGCGTTTCGGGATCTGAA
b-actin sense: 5’-CAACGAGCGGTTCCGAT
antisense; 5’-GCCACAGGATTCCATACCCA
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standards. Activation of AP-1 was assayed by EMSA
using a LightShift Chemiluminescent EMSA kit (Pierce,
Rockford, IL) according to the manufacture’si n s t r u c -
t i o n .B r i e f l y ,6μg of nuclear extract proteins were pre-
incubated with binding buffer (50% Glycerol, 100 mmol/
LM g C l 2,1 %N P - 4 0a n d1μg/μLP o l y( d I ￿dC)) for 5
min and then incubated with double-stranded biotin-
labeled oligonucleotide containing consensus AP-1 bind-
ing site (5’-CGCTTGATGATGAGTCAGCCGGAA-3’)
for 15 min at room temperature. For competition
experiments, unlabelled oligonucleotides were added to
the nuclear extracts at a 200-fold molar excess before
the addition of the biotin-labeled probe. DNA-protein
complexes were analyzed by electrophoresis in 4% poly-
acrylamide gels. Complexes were transferred to a nylon
membrane and crosslinked to the membrane using a
h a n d - h e l dU Vl a m pe q u i p p e dw i t h3 1 2n mb u l b s .
Migration of the biotinylated oligonucleotides and their
complexes was detected by chemiluminescence followed
by exposure of the membrane to X-ray films.
Statistical analysis
Data are presented as mean ± SD. All experiments were
performed at least three times. Data were analyzed by a
1 - w a yo r2 - w a yA N O V Aw i t hap o s th o cB o n f e r r o n i
test. Differences were considered significant at p < 0.05.
Results
LPS induces proinflammatory cytokine and iNOS
expression in microglia and astrocytes in which different
signaling molecules are involved
We first examined the effect of LPS on proinflammatory
cytokine and iNOS expression by murine primary
microglia and astrocytes, and explored the signaling
molecules involved. As shown in Fig.1, 0.5 μg/mL LPS
significantly increased TNF-a,I L - 1 b,I L - 6 ,M C P - 1a n d
iNOS mRNA levels in both cell types. Activation of
macrophages and microglia by LPS is thought to occur
(primarily) by binding of LPS to Toll-like receptor 4,
leading to activation of intracellular kinases (i.e., MAP
kinases) and transcription factors like NF-Ba n dA P - 1
[28]. We used inhibitors for MAP kinases and transcrip-
tion factors to determine whether activation of ERK1/2,
p38, JNK, NF-B, or AP-1 contribute to the induction
of proinflammatory cytokines and iNOS expression by
LPS in microglia and astrocytes. Pretreatment of micro-
glia and astrocytes with PD98059 (MEK inhibitor),
SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), sul-
fasalazine (NF-B inhibitor) [29], or curcumin (AP-1
inhibitor) [30] significantly inhibited LPS-induced TNF-
a expression in both microglia and astrocytes (Fig. 2A),
suggesting the involvement of ERK1/2, JNK, p38, NF-B
and AP-1 in TNF-a expression. All these inhibitors,
except for sulfasalazine, significantly inhibited LPS-
induced IL-1b and IL-6 expression in both microglia
and astrocytes (Fig. 2B and 2C), suggesting the involve-
m e n to fE R K 1 / 2 ,J N K ,p 3 8a n dA P - 1b u tn o tN F - Bi n
IL-1b and IL-6 expression. While PD98059, SP600125,
and curcumin inhibited MCP-1 and iNOS expression in
both microglia and astrocytes, SB203580 inhibited
MCP-1 and iNOS expression only in astrocytes, and sul-
fasalazine inhibited iNOS but not MCP-1 in both cell
types, suggesting that ERK1/2, JNK and AP-1 are
involved in LPS-induced expression of MCP-1 and
iNOS in microglia and astrocytes, that p38 is involved
in LPS-induced expression of MCP-1 and iNOS in
astrocytes but not microglia, and that NF-B is involved
in LPS-induced expression of iNOS but not MCP-1 in
both cell types. Taken together, ERK1/2, JNK and AP-1
are involved in LPS-induced TNF-a, IL-1b, IL-6, MCP-1
a n di N O Se x p r e s s i o ni nb o t hm icroglia and astrocytes.
p38 is involved in LPS-induced TNF-a,I L - 1 b,a n dI L - 6
expression in both microglia and astrocytes but is
involved in MCP-1 and iNOS expression in response to
LPS only in astrocytes. NF-Bi si n v o l v e do n l yi nL P S -
induced TNF-a and iNOS expression in both cell types.
Effects of resveratrol on cell viability and LPS-induced
morphological changes in glial cells
At all concentrations used in this study, resveratrol alone
or together with LPS did not show cytotoxicity to N9 cells,
primary microglia and astrocytes as examined by MTT
and LDH assays (Fig. 3A and 3B). Resveratrol treatment
did not induce apoptotic cell death as examined by nuclear
staining with Hoechst 33258 [31] (data not shown). A
marked change in N9 and primary microglial morphology
was observed at 8 h after stimulation with LPS (Fig. 3C):
the LPS-stimulated microglial cells changing from an
amoeboid shape to a multipolar (mostly bipolar, some tri-
polar) rod shape. LPS had no significant effect on astrocyte
morphology. Resveratrol (5-50 μM) had no significant
effect on microglial morphology induced by LPS (Fig. 3C).
Resveratrol alone also had no significant effect on micro-
glial cell and astrocyte morphology.
Effects of resveratrol on pro-inflammatory cytokine gene
expression and release
We next examined the effect of resveratrol on LPS-
induced pro-inflammatory cytokine expression and
release by microglia and astrocytes. As shown in Fig. 4,
0.5 μg/mL LPS significantly increased TNF-a, IL-1b, IL-
6 and MCP-1 mRNA levels in cells of the microglial cell
line N9, in primary microglia, and in astrocytes. Resver-
atrol inhibited LPS-induced cytokine mRNA expression
in N9 cells and primary microglia (Fig. 4A and 4B). In
primary astrocytes, resveratrol inhibited LPS-induced IL-
6 mRNA expression in a dose-dependent manner and
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Page 5 of 14Figure 2 Involvement of MAP kinases, NF-B and AP-1 in LPS-induced proinflammatory cytokine and iNOS expression in glial cells.
Murine primary microglia or astrocytes pretreated with or without PD98059 (50 μmol/L), SP600125 (20 μmol/L), SB203580 (20 μmol/L),
sulfasalazine (50 μmol/L), or curcumin (10 μmol/L) for 30 min were stimulated with 0.5 μg/mL LPS for 8 h. mRNA levels of proinflammatory
cytokines and iNOS were examined by real-time PCR. Results are presented as mean ± SD for duplicate measurement from 6 independent
experiments. *p < 0.05, **p < 0.01 compared with medium control;
# p < 0.05,
##p < 0.01 compared with treatment with 0.5 μg/ml LPS.
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sion only at a high concentration (50 μmol/L), but had
no effect on IL-1b gene expression (Fig. 4C). The effect
of resveratrol on LPS-induced pro-inflammatory cyto-
kine release by primary microglia and astrocytes was
examined by ELISA. Murine primary microglia and
astrocytes produced basal levels of IL-1b and MCP-1,
but not TNF-a or IL-6 (Fig. 5). Stimulation of these
cells with 0.5 μg/mL LPS significantly increased release
of TNF-a, IL-6, and MCP-1; and production of IL-b
(Fig. 5). Resveratrol dose-dependently inhibited LPS-
induced TNF-a,I L - b, IL-6 and MCP-1 release by
Figure 3 Effects of resveratrol on glial cell viability and LPS-induced morphological changes. (A-B), N9 cells, murine primary microglia, or
astrocytes were treated with different concentrations of resveratrol with or without 0.5 μg/ml LPS. Cell viability was examined by MTT (24 h) and
LDH (8 h) assays, respectively. The results are expressed as percentage of surviving cells over control cells. Data are presented as mean ± SD for
three separate experiments. (C) N9 cells, murine primary microglia and astrocytes were treated with different concentrations of resveratrol with
or without 0.5 μg/ml LPS for 8 h. Cell morphology was checked under microscope. Data are representative of three independent experiments
with similar results.
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induced release of TNF-a,I L - 1 b and IL-6 by primary
microglia at concentrations as low as 5 μM. Resveratrol
at tested concentrations (5-50 μmol/L) dose-dependently
inhibited LPS-induced IL-6 release by primary astro-
cytes, including at the minimal concentration of 5 μM.
Resveratrol also inhibited LPS-induced TNF-a and
MCP-1 release, but only at high concentration (50
μmol/L), but had no effect on IL-1b production by pri-
mary astrocytes. Taken together, these results are con-
sistent with the changes in cytokine mRNA levels (Fig.
4), and demonstrate that resveratrol differentially inhi-
bits pro-inflammatory cytokine expression and release
by LPS-activated microglia and astrocytes, with more
potency in microglia.
Effects of resveratrol on iNOS expression and NO
production
We also examined the effect of resveratrol on LPS-
induced iNOS expression and NO production by mouse
N9 cells, primary microglia and astrocytes. LPS signifi-
cantly stimulated iNOS gene expression in N9 cells, pri-
mary microglia and astrocytes. Resveratrol (5-50 μmol/
L) dose-dependently inhibited LPS-induced iNOS gene
expression in N9 cells and primary microglia. The
expression of iNOS induced by LPS in astrocytes was
inhibited by resveratrol only at a high concentration (50
μmol/L) (Fig. 6A). Consistent with its effect on iNOS
mRNA, resveratrol significantly reduced NO production
by LPS-stimulated primary microglia and astrocytes.
While the inhibitory effect of resveratrol on primary
microglia was dose dependent (Fig. 6B), with maximum
inhibition shown at 50 μmol/L, only a high concentra-
tion of resveratrol (50 μmol/L) inhibited LPS-induced
NO production in primary astrocytes. These results
indicate that resveratrol is more potent in inhibiting
LPS-induced iNOS expression and NO production by
microglia than by astrocytes. It has been reported that
LPS potently induces NO release in microglia cells by
de novo synthesis of iNOS [24]. Thus, the effect of
Figure 4 Resveratrol inhibits LPS-induced cytokine mRNA expression in glial cells. N9 cells (A), murine primary microglial cells (B), or
astrocytes (C) were incubated with 0.5 μg/ml LPS in the presence or absence of different concentrations of resveratrol (RV) for 8 h. Cells were
collected, and RNA was extracted to detect TNF-a, IL-1b, IL-6 and MCP-1 mRNA by RT-PCR. Data are presented as mean ± SD for three
independent experiments. *P < 0.05, **P < 0.01 compared with treatment with LPS alone. Representative gels are shown.
Lu et al. Journal of Neuroinflammation 2010, 7:46
http://www.jneuroinflammation.com/content/7/1/46
Page 8 of 14resveratrol on LPS-induced NO release may be due to
the reduction of iNOS expression.
Effect of resveratrol on MAP kinase activation by LPS
Since the above results showed that MAP kinases are
differentially involved in LPS-induced pro-inflammatory
cytokine expression in microglia and astrocytes, we next
investigated the ability of resveratrol to interfere with
phosphorylation of MAP kinases in response to LPS. As
N9 cells and primary microglia responded to LPS and
resveratrol with similar patterns (Fig. 4) and the number
of microglia that can be cultured from neonatal mice is
limited, N9 cells were used in this and the following
mechanistic studies. LPS significantly induced phosphor-
ylation of ERK1/2, p38 and JNK in both N9 microglial
cells and primary astrocytes. Basal level phosphorylation
of ERK1/2 and JNK was detected in astrocytes. Resvera-
trol at a high concentration (50 μmol/L) slightly inhib-
ited LPS-induced JNK phosphorylation in astrocytes but
not in N9 cells, and had no effect on LPS-induced phos-
phorylation of ERK1/2 and p38 in either cell type (Fig.
7). These results suggest that, among MAP kinases acti-
vated by LPS, resveratrol is capable of inhibiting JNK
activation in astrocytes. Thus, the inhibitory effect of
resveratrol on LPS-induced proinflammatory cytokine
expression and release may be mainly mediated by
signaling molecules downstream of MAP kinases.
Effects of resveratrol on NF-B and AP-1 activation by
LPS
NF-B and AP-1 are implicated in regulation of the
expression of pro-inflammatory cytokines and iNOS by
LPS [32]. Our results show that NF-Ba n dA P - 1p l a y
different roles in LPS-induced proinflammatory cytokine
and iNOS expression in microglia and astrocytes (Fig. 2).
The effect of resveratrol on activation of NF-B and AP-
1 by LPS was examined by luciferase reporter assay and
EMSA, respectively. Luciferase reporter assay analysis
showed that LPS significantly induces NF-B activation
in primary microglia (Fig. 8A) and astrocytes (Fig. 8B).
Resveratrol dose-dependently suppressed LPS-induced
NF-B activation in both cell types. After LPS stimula-
tion, DNA binding activity of nuclear extracts to AP-1
consensus oligonucleotides was significantly increased in
N9 cells (Fig. 9A) but only slightly increased in astrocytes
(Fig. 9B). Binding specificity was verified by incubating
nuclear extracts from LPS-stimulated cells with excess
unlabeled specific oligonucleotide probe (Fig. 9A and B,
Figure 5 Effect of resveratrol on LPS-induced cytokine production. Murine primary microglial cells or astrocytes were treated with/without
various concentrations of resveratrol (RV) in serum-free DMEM for 30 min followed by 0.5 μg/mL LPS for another 24 h. TNFa (A), IL-6 (C), MCP-1
(D) in supernatants and IL-1b (B) in cell lysate were detected by ELISA. Results are presented as mean ± SD for duplicate measurements from 3
independent experiments. **P < 0.01 compared with medium control or treatment with 50 μM RV alone.
## P < 0.01 compared with treatment
with 0.5 μg/ml LPS.
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Page 9 of 14the last lane). Treatment with resveratrol alone inhibited
basal binding activity of AP-1 in N9 cells (Fig, 9A). The
increased AP-1 binding activity induced by LPS was
inhibited in resveratrol-pretreated N9 cells but not in
astrocytes (Fig. 9A and 9B). These results provide a
mechanistic basis for the capacity of resveratrol to differ-
entially inhibit LPS-induced microglia and astrocyte
activation at the levels of NF-B and AP-1.
Discussion
The present study demonstrates that murine microglia
and astrocytes produce proinflammatory cytokines and
NO in response to LPS in a similar pattern with some
differences in the signaling molecules involved.
Resveratrol limited LPS-stimulated microglia and astro-
cyte activation with different potencies and through
inhibiting different signaling molecules. To our knowl-
edge, this is the first report of a difference between
microglial cell and astrocyte in response to LPS, and of
a difference in the capacity of resveratrol to protect
microglia and astrocytes from inflammatory insults.
Microglia are the main resident immuno-competent
and phagocytic cells in CNS. Astrocytes also play an
important role in regulating inflammation in the CNS.
LPS is capable of inducing production of pro-inflamma-
tory cytokines and NO in both microglia and astrocytes
[23,33,34]. Our study shows that LPS significantly
induces the expression and production of pro-inflamma-
tory cytokines (TNF-a,I L - 1 b,I L - 6 ,a n dM C P - 1 ) ,a n d
enhances the expression of iNOS and production of
N O ,b yp r i m a r ym i c r o g l i aa n dp r i m a r ya s t r o c y t e s .N 9
cells expressed pro-inflammatory cytokines and iNOs at
the mRNA level in response to LPS in a pattern similar
to that of primary microglia. These results indicate that
the inflammatory responses of microglial cell and astro-
cyte to LPS are similar.
By binding to TLR4, LPS activates NF-Bt h r o u g h
TAK1, and activates AP-1t h r o u g ht h eT A K 1 - M A P
kinase (ERK1/2, p38, JNK) pathway. NF-Ba n dA P - 1
control inflammatory responses through the induction
of inflammatory cytokines [28,32]. It has been reported
that, in microglia, LPS stimulates TNF-a expression
through activation of ERK1/2, p38, JNK/AP-1 and NF-
B [34-36]; stimulates IL-6 and MCP-1 expression
through JNK2 and AP-1; stimulates IL-6 expression
through p38 [34,37]; and stimulates iNOS expression
through ERK1/2, p38 and NF-B [35,38]. Our data
demonstrate that, in addition to these mechanisms, LPS
stimulates IL-1b expression through activation of ERK1/
2, JNK, p38 and AP-1; stimulates IL-6 and MCP-1
expression through ERK1/2; and stimulates iNOS
expression through JNK and AP-1. Taken together,
these data suggest that MAP kinases, NF-Ba n dA P - 1
are differentially involved in the production of proin-
flammatory cytokines and iNOS in microglia in response
to LPS.
There are only a few reports regarding the involve-
ment of MAP kinases and transcription factors in LPS-
induced expression of inflammatory mediators in astro-
cytes. Treatment of astrocytes with LPS alone induces
iNOS expression through ERK1/2- and NF-B-related
signaling pathways [39]. A combination of LPS and IFN-
g results in TNF-a and iNOS expression through activa-
tion of ERK1/2, p38 and JNK [39,40]. Our present study
shows that LPS significantly induces ERK1/2, p38, and
JNK phosphorylation and NF-B activation but only
slightly activates AP-1 in astrocytes, and that LPS
induces proinflammatory cytokine (TNF-a,I L - 1 b,I L - 6
Figure 6 Resveratrol inhibits LPS-stimulated iNOS mRNA
expression and NO production. N9 cells, murine primary
microglial cells, or astrocytes were incubated with 0.5 μg/mL LPS in
the presence or absence of different concentrations of resveratrol
(RV). iNOS mRNA was examined by RT-PCR after 8 h incubation (A);
NO in supernatant was measure by the Griess reaction after 24 h
incubation (B). Results are presented as mean ± SD for 3
independent experiments. **P < 0.01 compared with medium
control or treatment with 50 μM RV alone.
## P < 0.01 compared
with treatment with 0.5 μg/ml LPS.
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Page 10 of 14and MCP-1) and iNOS expression in astrocytes through
activation of ERK1/2, p38, JNK and AP-1. NF-B is only
involved in LPS-induced TNF-a and iNOS expression in
astrocytes. Comparison of the results for microglia with
those for astrocytes shows that similar signaling mole-
cules (MAP kinases, NF-B and AP-1) are involved in
LPS-induced TNF-a,I L - 1 b and IL-6 expression, except
that p38 is involved in MCP-1 and iNOS expression
only in astrocytes and not in microglia. This may be due
to differences in the biological characteristics of these
two cell types.
Resveratrol has been reported to inhibit LPS-induced
NO and PGE2 production by rat astroglioma cells [22],
and to inhibit TNF-a, iNOS expression and NO produc-
tion by a mouse microglial cell line [19,20]. Our results
show that, in addition to inhibiting LPS-stimulated
TNF-a and NO production, resveratrol also inhibits
LPS-induced expression and production of IL-1b,I L - 6 ,
and MCP-1 in primary microglia and in the microglial
cell line N9 (Fig. 4 and 5). At the tested concentrations
(5-50 μM), resveratrol significantly inhibited LPS-
induced proinflammatory cytokine production by pri-
mary microglia (TNF-a,I L - 1 b and IL-6) and astrocytes
(IL-6), including significant inhibition at the lowest con-
centration of 5 μM. Furthermore, our results suggest
that resveratrol differentially regulates the production of
pro-inflammatory molecules and NO by microglia rela-
tive to astrocytes. Resveratrol dose-dependently inhibited
the production of NO, TNF-a,I L - 6a n dM C P - 1b yp r i -
mary microglia in response to LPS, but only inhibited
NO, TNF-a and MCP-1 production at a high concen-
tration (50 μmol/L) and had no effect on IL-1b produc-
tion in astrocytes (Fig. 5). Therefore, resveratrol has a
more potent suppressive effect on the production of
pro-inflammatory molecules by LPS-activated microglia.
Existing observations from both in vitro and in vivo
studies have demonstrated that resveratrol has differen-
tial effects on MAP kinases and can inhibit the
Figure 7 Effect of resveratrol on MAP kinase activation by LPS in glial cells. N9 cells (A) or murine primary astrocytes (B) were treated with
various concentrations of resveratrol (RV) for 1 h followed by LPS stimulation (N9 cells: 0.2 μg/ml for 30 min; astrocytes: 0.5 μg/ml for 20 min).
ERK1/2, p38, and JNK phosphorylation were examined by western blotting. Data are presented as mean ± SD for three independent
experiments. Representative gels are shown.
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cific manner [41,42]. Bi et al. [20] reported that resvera-
trol treatment (48 h) of LPS-stimulated (1 μg/mL) N9
cells inhibited LPS-induced p38 phosphorylation. Our
study shows that LPS activates p38 in microglia and
astrocytes, but we found that resveratrol has no effect
on p38 phosphorylation in these cells (Fig. 7). The dis-
crepancy may be due to differences in cell origin and
experimental conditions. As our studies show that
resveratrol has no effect on LPS-induced phosphoryla-
tion of ERK1/2 in either microglia or astrocytes, and
only slightly inhibits LPS-induced JNK phosphorylation
in astrocytes, we then examined the effect of resveratrol
on signaling molecules downstream of MAPKs. NF-B
is a common regulatory element in the promoter region
of many pro-inflammatory cytokines. Our studies show
that resveratrol attenuates LPS-stimulated NF-B activa-
tion in murine primary microglia and astrocytes. Consis-
tently, other researchers have reported that resveratrol
can suppress LPS-induced degradation of IBa in the
microglial cell line N9 [20], and can suppress nuclear
translocation and activation of NF-B in rat C6 astro-
glioma cells [22]. Resveratrol is an activator of SIRT1,
which has been reported to inhibit NF-B activity
through deacetylation of the RelA/p65subunit of NF-B
[43]. The inhibition of SIRT1 signalingby LPS is partially
responsible for the activation of NF-B pathways and
subsequent generation of TNF-a in Kupffer cells and
macrophages [44]. Therefore, it should be quite interest-
ing to investigate whether activation of SIRT1 signaling
also contributes to the inhibitory effect of resveratrol on
NF-B activation by LPS in glial cells. Recent studies
have shown that resveratrol inhibits LPS-induced NF-B
activation by targeting TANK-binding kinase 1 and
RIP1 in the TRIF complex in a murine macrophage cell
line [45]. Whether the inhibitory effect of resveratrol on
LPS-induced NF-B activation in microglia and astro-
cytes is mediated by a similar mechanism as that in
macrophages will require further investigation. In addi-
tion to NF-B, AP-1 has also beenshown to be involved
in inflammatory responses in responseto LPS. Our
results show that AP-1 is involved in LPS-induced IL-1b
expression and release by microglia and astrocytes.
Resveratrol inhibits LPS-induced AP-1 activation in
microglia but not astrocytes, which may explain why
resveratrol inhibits IL-1b expression and release by
m i c r o g l i ab u tn o tb ya s t r o c y t e s .A P - 1i sf o r m e db y
dimerization of Jun proteins (c-Jun, JunB and JunD) or
Figure 8 Resveratrol inhibits activation of NF-B by LPS. Murine
primary microglial cells (A) or astrocytes (B) transfected with an NF-
B luciferase reporter plasmid and a pRL-TK-Renilla vector were
treated with LPS and different concentrations of resveratrol (RV) for
16 h. Cell lysates were prepared and luciferase activities were
measured. Results are presented as mean ± SD for 3 independent
experiments. **p < 0.01 compared with medium control or
treatment with 50 μM RV alone.
#p < 0.05,
##p < 0.01 compared
with treatment with LPS.
Figure 9 Effect of resveratrol on LPS-induced AP-1 activation.
N9 cells (A) or murine primary astrocytes (B), pretreated with
different concentrations of resveratrol (RV) for 30 min, were
stimulated with 0.5 μg/mL LPS for 4 h. DNA-binding activity of AP-1
in the nuclear extract was examined by EMSA using a biotin-labeled
AP-1 consensus probe. A 200-fold molar excess of cold probe was
used to confirm the specificity. Data are representative of 3 separate
experiments with similar results.
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(c-Fos, FosB, Fra-1 and Fra-2) [46], and resveratrol has
been reported to inhibit c-fos mRNA expression and
AP-1 DNA binding in mouse skin [47]. We found that
resveratrol has no effect on LPS-induced JNK phosphor-
ylation but inhibits LPS-induced AP-1 activation in
microglia. Contrarily, resveratrol slightly inhibits LPS-
induced phosphorylation of JNK but has no effect on
AP-1 activation by LPS in astrocytes. The contrary effect
of resveratrol on JNK phosphorylation and AP-1 activa-
tion in microglia and astrocytes may be due to involve-
ment of AP-1 components other than c-Jun in LPS-
induced AP-1 activation in microglia, and LPS may acti-
vate different AP-1 components in microglia and astro-
cytes, but these possibilities need further investigation.
Collectively, the different effects of resveratrol on proin-
flammatory cytokine and iNOS expression in response
to LPS in microglia and astrocytes may be due to differ-
ent effects of resveratrol on NF-B and AP-1 activation
in these two cell types. In addition, differences in biolo-
gical characteristics of microglia and astrocytes may also
contribute to their unique response to LPS and
resveratrol.
Microglia and astrocytes play important roles in host
defense during brain infection and inflammation. These
cells produce pro-inflammatory mediators in response
to pathologic stimuli such as LPS. As a potent source of
proinflammatory cytokines and chemokines, microglia
and astrocytes are pivotal in the progression of CNS dis-
eases including Alzheimer’s disease [12], multiple sclero-
sis [8,9], Parkinson’s disease [10,11], and brain injury.
Therefore, a therapeutic approach aimed at suppressing
activation of microglia and astrocytes may alleviate
inflammation in the CNS and thus retard the progres-
sion of these diseases. Our results suggest that the
extent of inflammatory responses induced by LPS in
microglia and astrocytes could be limited by resveratrol,
with different potencies. Therefore, resveratrol is a nat-
ural product with therapeutic potential against CNS dis-
eases involving overproduction of pro-inflammatory
cytokines and NO.
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